Canine dilated cardiomyopathy drugs are used to treat heart muscle diseases which causes the heart to weaken and enlarge. This results in weaken contraction and poor pumping ability of the heart. The canine dilated cardiomyopathy is prevalent in certain breeds of dog and observed to be rare in crossbreeds dogs. Canine dilated cardiomyopathy drugs are directed at enhancing systolic (pump) function of the heart, dilating the peripheral blood vessels to lower ventricular workload, controlling heart rate and cardiac arrhythmias. Canine dilated cardiomyopathy drugs treatment goals are achieved by the administration of cardiac medication which may be delivered through injections in an emergency situation or orally in stable animals.
This report contains market size and forecasts of Canine Dilated Cardiomyopathy Drug in global, including the following market information:
Global Canine Dilated Cardiomyopathy Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Canine Dilated Cardiomyopathy Drug Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Canine Dilated Cardiomyopathy Drug companies in 2021 (%)
The global Canine Dilated Cardiomyopathy Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Canine Dilated Cardiomyopathy Drug include C. H. Boehringer Sohn AG & Co., KG, Merck & Co., Dechra Pharmaceuticals PLC, Bayer AG, Orion, SAVA Vet, Elanco and Zoetis Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Canine Dilated Cardiomyopathy Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Canine Dilated Cardiomyopathy Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Canine Dilated Cardiomyopathy Drug Market Segment Percentages, by Type, 2021 (%)
Oral
Injectable
Global Canine Dilated Cardiomyopathy Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Canine Dilated Cardiomyopathy Drug Market Segment Percentages, by Application, 2021 (%)
Online
Offline
Global Canine Dilated Cardiomyopathy Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Canine Dilated Cardiomyopathy Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Canine Dilated Cardiomyopathy Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Canine Dilated Cardiomyopathy Drug revenues share in global market, 2021 (%)
Key companies Canine Dilated Cardiomyopathy Drug sales in global market, 2017-2022 (Estimated), (MT)
Key companies Canine Dilated Cardiomyopathy Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
C. H. Boehringer Sohn AG & Co.
KG, Merck & Co.
Dechra Pharmaceuticals PLC
Bayer AG
Orion
SAVA Vet
Elanco
Zoetis Inc.